---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-063076"
form_type: "8-K"
ticker: null
cik: "0001773427"
company_name: "SpringWorks Therapeutics, Inc."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T16:29:42.840674+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# SpringWorks stockholders re-elect Freda Lewis-Hall as director, ratify EY, approve say-on-pay

## Summary
- Freda Lewis-Hall elected Class II director: 50.3M for, 15.8M withheld, 3.4M abstentions.
- Ratification of Ernst & Young as FY2024 auditor: 69.5M for, 5,709 against, 10,294 abstentions.
- Non-binding advisory vote on executive compensation approved: 38.3M for, 27.8M against, 3.4M abstentions.
- All three proposals passed at May 16, 2024 annual meeting.

## SEC filing metadata
- accession: 0001104659-24-063076
- form_type: 8-K
- cik: 0001773427
- company_name: SpringWorks Therapeutics, Inc.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1773427/000110465924063076/0001104659-24-063076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1773427/000110465924063076/tm2414870d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-063076
- JSON: https://secwatch.observer/filing/0001104659-24-063076.json
- Plain text: https://secwatch.observer/filing/0001104659-24-063076.txt

## Source-grounded claims
- claim_id: 559306c1f2cc606e7a5ee7b80f1580ce3decd431
  claim: SpringWorks Therapeutics, Inc. shareholders approved Non-Binding Advisory Vote on Executive Compensation at the 2024-05-16 meeting.
  evidence_excerpt: Proposal 3 - Non-Binding Advisory Vote on Executive Compensation The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the annual meeting of stockholders. The results of such vote were as follows: Votes For Votes Against Abstentions/ Non-Votes 38,332,463 27,761,536 3,407,326
  evidence_url: https://www.sec.gov/Archives/edgar/data/1773427/000110465924063076/0001104659-24-063076-index.htm
- claim_id: 86c797b6dd4c35b1c3af1c2f766bebc62ae12ad5
  claim: SpringWorks Therapeutics, Inc. shareholders approved Election of Freda Lewis-Hall as Class II Director at the 2024-05-16 meeting.
  evidence_excerpt: Proposal 1 - Election of Directors The stockholders elected the person named below to serve as a Class II director of the Company for a three-year term that expires at the Company’s annual meeting of stockholders in 2027 and until her successor has been duly elected and qualified, subject to her earlier death, resignation or removal. The results of such vote were as follows: Director Name Votes For Withheld Abstentions/ Non-Votes Freda Lewis-Hall 50,328,375 15,800,834 3,372,116
  evidence_url: https://www.sec.gov/Archives/edgar/data/1773427/000110465924063076/0001104659-24-063076-index.htm
- claim_id: b6bd558cde3411dc9e1a96a337de630149d04b9f
  claim: SpringWorks Therapeutics, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2024-05-16 meeting.
  evidence_excerpt: Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of such vote were as follows: Votes For Votes Against Abstentions 69,485,322 5,709 10,294
  evidence_url: https://www.sec.gov/Archives/edgar/data/1773427/000110465924063076/0001104659-24-063076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.